Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

At 31, Rohan should have been planning his next trek in Himachal, not learning how to pronounce adenocarcinoma. Fit, cheerful ...

Sansum Clinic and Ridley-Tree Cancer Center will share a panel discussion that was presented on prostate health. To view the video presentation, click ...

At 31, Rohan should have been planning his next trek in Himachal, not learning how to pronounce adenocarcinoma. Fit, cheerful, and the office’s go-to for wellne ...

BALTIMORE, Nov. 13, 2025 (GLOBAL NEWSWIRE) — The Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), and the Prostate Cancer Foundation (PCF) today ...

I’m a 64-year-old man who was recently diagnosed with an enlarged prostate after experiencing issues with frequent urination, ...

Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe that resists the breakdown of certain compounds in the body, giving doctors ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Thousands of men living with advanced, hormone-sensitive prostate cancer (HSPC) in England and Wales will be able to access Bayer's Nubeqa, after it was recommended for NHS use by reimbursement ...

A new procedure now available at Columbus Regional aims to give men with enlarged prostates a chance to reclaim their ...